Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who wrote (789)	9/27/1998 12:35:00 PM
From: Biomaven	Read Replies (1) of 965

Well maybe one reason CNTO paid a healthy chunk for Retavase is that they know (or strongly suspect) that it works very well when combined with ReoPro. If this is correct, and the ReoPro/Retavase combination becomes the standard therapy for MI, CNTO will have made a very good acquisition in Retavase, no matter if they overpaid or not. Here is a quote from their 10-Q: The Company believes a potential advantage of the acquisition of Retavase lies in the possibility that ReoPro(R) (abciximab) and Retavase, administered in combination, may prove to have a therapeutic advantage over monotherapy for acute myocardial infarction patients. Two Phase II clinical trials currently are underway to evaluate the approach of using ReoPro in conjunction with a fibrinolytic product in the management of heart attack patients. I hold my small stake in CNTO mostly because I believe in ReoPro/Retavase and because there is a huge short position that may need to exit if I am right. The latest ReoPro results were very strong, and I am hoping for more of the same. I certainly didn't buy my stock because of any recommendation from an investment banker. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next